Eltrombopag clinical trials
Also written Promacta, Revolade, SB497115 and ETB115.
How each study uses eltrombopag is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the eltrombopag studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 20 Nov 2008 · PROMACTA · NDA 022291 (FDA, Drugs@FDA)
- European Union
- 11 Mar 2010 · Revolade · EMEA/H/C/001110 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
134 studies that test it; most in 2012 (13); 1 more planned to start later
| Year | Studies |
|---|---|
| 2005 | 3 |
| 2006 | 5 |
| 2007 | 5 |
| 2008 | 3 |
| 2009 | 11 |
| 2010 | 8 |
| 2011 | 7 |
| 2012 | 13 |
| 2013 | 13 |
| 2014 | 8 |
| 2015 | 7 |
| 2016 | 4 |
| 2017 | 3 |
| 2018 | 10 |
| 2019 | 7 |
| 2020 | 9 |
| 2021 | 3 |
| 2022 | 3 |
| 2023 | 2 |
| 2024 | 2 |
| 2025 | 7 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 49 · Other 86
GlaxoSmithKline (29) · Novartis Pharmaceuticals (18) · National Heart, Lung, and Blood Institute (NHLBI) (7) · M.D. Anderson Cancer Center (6) · Institute of Hematology & Blood Diseases Hospital, China (3) · Assiut University (3) · Weill Medical College of Cornell University (3) · Associazione Qol-one (2)
Often tested with
Tested in the same studies.
Cyclosporine (5) · Romiplostim (3) · Diacerein (2) · Dexamethasone (2) · Rituximab (2) · Thymoglobulin (1) · Rosuvastatin (1) · Adagrasib (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test eltrombopag.
- Nov 2027Sequential rhTPO and Eltrombopag Following Glucocorticoids for Severe Adult ITPPhase 4 · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Studies
Open first, then newest update. How each study uses eltrombopag is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 135
- Part B- G1X-CGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Linked Chronic Granulomatous DiseaseEnrolling by invitationPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT07113743Written as Eltrombopag
- Eltrombopag Plus Telitacicept vs. Eltrombopag Alone for Steroid-refractory/Relapsed ITPNot yet recruitingPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT07687134Written as Eltrombopag
- A Study of Ianalumab in Addition to Eltrombopag in Pediatric Patients With Primary ITP Who Failed Corticosteroids.Not yet recruitingPhase 2Novartis PharmaceuticalsNCT07660172Written as Eltrombopag
- Early Initiation of Oral Therapy With Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA)RecruitingPhase 2National Heart, Lung, and Blood Institute (NHLBI)NCT04304820Written as Eltrombopag
- Sequential rhTPO and Eltrombopag Following Glucocorticoids for Severe Adult ITPNot yet recruitingPhase 4Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyNCT07189910Written as Eltrombopag
- Eltrombopag Induced Liver Dysfunction During Treatment of Immunethrombocytopenic PurpuraRecruitingNot applicableSohag UniversityNCT07093606Written as Eltrombopag
- Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic DiseaseRecruitingPhase 4Wei ZhaoNCT03844360Written as Eltrombopag
- Eltrombopag for Chemotherapy-induced ThrombocytopeniaRecruitingPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT04600960Written as Eltrombopag
- Role of Eltrombopag as First Line Therapy in Primary Immune Thrombocytopenia.RecruitingPhase 1/2Renata PLCNCT06531018Written as Eltrombopag 25 MG
- Ripertamab Plus Eltrombopag vs. Eltrombopag in ITP Patients Post-Steroid FailureNot yet recruitingNot applicableWuhan Union Hospital, ChinaNCT06790888Written as Ripertamab/Eltrombopag
- Eltrombopag for Peripheral Blood Stem Cell HarvestRecruitingPhase 2National Taiwan University HospitalNCT05961410Written as Eltrombopag olamine
- REscuing Bone Marrow Function in Patients with AplaStic AnaEmia and Bone Marrow FaiLure Post AllogEneiC Transplantation 2Not yet recruitingPhase 1/2Melbourne HealthNCT06607367Written as Eltrombopag (Revolade®)
- Outcomes in Bone Marrow Aplasia.Not yet recruitingPhase 3Assiut UniversityNCT06493981Written as Eltrombopag
- Immune Thrombocytopenia Management in AdultsRecruitingPhase 4Nahda UniversityNCT05861297Written as Eltrombopag
- Study of Efficacy and Safety of Eltrombopag in Lower-risk MDS Patients With Platelet Transfusion DependenceActive, not recruitingPhase 2Novartis PharmaceuticalsNCT04797000Written as Eltrombopag
- Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 MutationsSuspendedPhase 2Abhay Singh, MD MPHNCT06630221Written as Eltrombopag (EPAG)
- Pilot Trial of Eltrombopag in Patients Undergoing Chemotherapy for Malignant Solid TumorsTerminatedPhase 1University of California, DavisNCT04485416Written as Eltrombopag
- Eltrombopag for Fanconi AnemiaActive, not recruitingPhase 2National Heart, Lung, and Blood Institute (NHLBI)NCT03206086Written as Eltrombopag
- A Phase II Dose-escalation Study Characterizing the PK of Eltrombopag in Pediatric Patients With Previously Untreated or Relapsed Severe Aplastic Anemia or Recurrent Aplastic AnemiaCompletedPhase 2Novartis PharmaceuticalsNCT03025698Written as Eltrombopag
- Eltrombopag Olamine in Improving Platelet Recovery in Older Patients With Acute Myeloid Leukemia Undergoing ChemotherapyCompletedPhase 2Case Comprehensive Cancer CenterNCT02071901Written as eltrombopag olamine
See all 135 studies that test eltrombopag →
Given beside what is tested · 7 — eltrombopag is usual care or a partner of the new treatment
- High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With SplenomegalyRecruitingPhase 2M.D. Anderson Cancer CenterNCT06345495Written as Eltrombopag
- The Efficacy and Safety of HCQ Plus TPO-RA in ANA Positive ITPRecruitingNot applicableYunfeng ChengNCT06479291Written as Eltrombopag
- Zanubrutinib and Eltrombopag as Second-line Treatment in Adults With Primary Immune ThrombocytopeniaNot yet recruitingPhase 2Peking University People's HospitalNCT05369377Written as Eltrombopag
- A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed SteroidsActive, not recruitingPhase 3Novartis PharmaceuticalsNCT05653219Written as Eltrombopag
- The Combination of ATRA and Eltrombopag as the Treatment of Steroid-resistant/Relapse ITP Based on MSC-C5b-9CompletedPhase 3Peking University People's HospitalNCT05438875Written as Eltrombopag
- Phase II Study of Lenalidomide and Eltrombopag in Patients With Symptomatic AnemiaCompletedPhase 2Albert Einstein College of MedicineNCT01772420Written as Eltrombopag Olamine
- Eltrombopag Plus rhTPO Versus Eltrombopag for ITP During the COVID-19 Pandemic (ELABORATE-19)Status unknownPhase 2Peking University People's HospitalNCT04516837Written as Eltrombopag
As the comparator · 4 — what is tested is compared with eltrombopag
- Eltrombopag Combining Rituximab Versus Eltrombopag in the Management of Primary Immune Thrombocytopenia (ITP) in AdultsRecruitingPhase 4Institute of Hematology & Blood Diseases Hospital, ChinaNCT04518475Written as eltrombopag
- A Randomized Trial Comparing Optimized rhTPO Treatment With Eltrombopag Treatment in Pre-treated ITP PtsCompletedPhase 4Institute of Hematology & Blood Diseases Hospital, ChinaNCT05583838Written as Eltrombopag
- Efficacy and Safety of rhTPO and Eltrombopag in Patients With Primary Immune Thrombocytopenia (ITP)Status unknownPhase 4Wuhan Union Hospital, ChinaNCT03771378Written as eltrombopag
- A Phase 3, Multicenter, Randomized, Double-blind,Active-controlled, Parallel-group Trial With an Open-labelExtension Phase to Evaluate the Efficacy and Safety of OralE5501 Versus Eltrombopag, in Adults With Chronic ImmuneThrombocytopenia (Idiopathic Thrombocytopenic Purpura)TerminatedPhase 3Eisai Inc.NCT01433978Written as Eltrombopag
Codes
What other systems call eltrombopag · ClinicalTrials.gg INT005109
- MeSH (NLM) C520809eltrombopagConfirmed NLM, Wikidata
- UNII (FDA) S56D65XJ9GELTROMBOPAGConfirmed FDA, NLM, Wikidata
- RxNorm 711942Confirmed FDA, Wikidata
- Wikidata Q411588eltrombopagConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C71634EltrombopagOne source FDA
- DrugBank DB06210One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C520809 | eltrombopag | Confirmed NLM, Wikidata |
| UNII (FDA) | S56D65XJ9G | ELTROMBOPAG | Confirmed FDA, NLM, Wikidata |
| RxNorm | 711942 | — | Confirmed FDA, Wikidata |
| Wikidata | Q411588 | eltrombopag | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C71634 | Eltrombopag | One source FDA |
| DrugBank | DB06210 | — | One source Wikidata |
Also registered as eltrombopag olamine (UNII 4U07F515LG · RxNorm 735651).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.